|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.
|
|
2
|
Sun M, Thuret R, Abdollah F, Lughezzani G,
Schmitges J, Tian Z, Shariat SF, Montorsi F, Patard JJ, Perrotte P
and Karakiewicz PI: Age-adjusted incidence, mortality, and survival
rates of stage-specific renal cell carcinoma in North America: a
trend analysis. Eur Urol. 59:135–141. 2011.
|
|
3
|
Campbell SC, Novick AC, Belldegrun A,
Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ,
Matin SF, Russo P and Uzzo RG: Guideline for management of the
clinical T1 renal mass. J Urol. 182:1271–1279. 2009.
|
|
4
|
Huang WC, Levey AS, Serio AM, Snyder M,
Vickers AJ, Raj GV, Scardino PT and Russo P: Chronic kidney disease
after nephrectomy in patients with renal cortical tumours: a
retrospective cohort study. Lancet Oncol. 7:735–740. 2006.
|
|
5
|
del Laguna MP, Zondervan PJ and de la
Rosette JJ: Focal therapy in the management of small renal masses.
Curr Opin Urol. 22:372–378. 2012.
|
|
6
|
Beitler JJ, Makara D, Silverman P and
Lederman G: Definitive, high-dose-per-fraction, conformal,
stereotactic external radiation for renal cell carcinoma. Am J Clin
Oncol. 27:646–648. 2004.
|
|
7
|
Blomgren H, Lax I, Näslund I and Svanström
R: Stereotactic high dose fraction radiation therapy of
extracranial tumors using an accelerator. Clinical experience of
the first thirty-one patients. Acta Oncol. 34:861–870. 1995.
|
|
8
|
Gunvén P, Blomgren H and Lax I:
Radiosurgery for recurring liver metastases after hepatectomy.
Hepatogastroenterology. 50:1201–1204. 2003.
|
|
9
|
Huang WY, Jen YM, Lee MS, Chang LP, Chen
CM, Ko KH, Lin KT, Lin JC, Chao HL, Lin CS, et al: Stereotactic
body radiation therapy in recurrent hepatocellular carcinoma. Int J
Radiat Oncol Biol Phys. 84:355–361. 2012.
|
|
10
|
Lax I, Blomgren H, Näslund I and Svanström
R: Stereotactic radiotherapy of malignancies in the abdomen.
Methodological aspects. Acta Oncol. 33:677–683. 1994.
|
|
11
|
Stinauer MA, Kavanagh BD, Schefter TE,
Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M and
Raben D: Stereotactic body radiation therapy for melanoma and renal
cell carcinoma: impact of single fraction equivalent dose on local
control. Radiat Oncol. 6:342011.
|
|
12
|
Svedman C, Karlsson K, Rutkowska E,
Sandström P, Blomgren H, Lax I and Wersäll P: Stereotactic body
radiotherapy of primary and metastatic renal lesions for patients
with only one functioning kidney. Acta Oncol. 47:1578–1583.
2008.
|
|
13
|
Svedman C, Sandström P, Pisa P, Blomgren
H, Lax I, Kälkner KM, Nilsson S and Wersäll P: A prospective Phase
II trial of using extracranial stereotactic radiotherapy in primary
and metastatic renal cell carcinoma. Acta Oncol. 45:870–875.
2006.
|
|
14
|
Teh B, Bloch C, Galli-Guevara M, Doh L,
Richardson S, Chiang S, Yeh P, Gonzalez M, Lunn W, Marco R, et al:
The treatment of primary and metastatic renal cell carcinoma (RCC)
with image-guided stereotactic body radiation therapy (SBRT).
Biomed Imaging Interv J. 3:e62007.
|
|
15
|
Wersäll PJ, Blomgren H, Lax I, Kälkner KM,
Linder C, Lundell G, Nilsson B, Nilsson S, Näslund I, Pisa P and
Svedman C: Extracranial stereotactic radiotherapy for primary and
metastatic renal cell carcinoma. Radiother Oncol. 77:88–95.
2005.
|
|
16
|
Wulf J, Haedinger U, Oppitz U, Thiele W,
Mueller G and Flentje M: Stereotactic radiotherapy for primary lung
cancer and pulmonary metastases: a noninvasive treatment approach
in medically inoperable patients. Int J Radiat Oncol Biol Phys.
60:186–196. 2004.
|
|
17
|
Siva S, Pham D, Gill S, Corcoran NM and
Foroudi F: A systematic review of stereotactic radiotherapy
ablation for primary renal cell carcinoma. BJU Int. 110:E737–E743.
2012.
|
|
18
|
Karnofsky DA, Abelmann WH, Craver LF and
Burchenal JH: The use of the nitrogen mustards in the palliative
treatment of carcinoma. With particular reference to bronchogenic
carcinoma. Cancer. 1:634–656. 1948.
|
|
19
|
Cox JD, Stetz J and Pajak TF: Toxicity
criteria of the Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research and Treatment of Cancer (EORTC).
Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995.
|
|
20
|
Dawson LA, Kavanagh BD, Paulino AC, Das
SK, Miften M, Li XA, Pan C, Ten Haken RK and Schultheiss TE:
Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys.
76(3 Suppl): S108–S115. 2010.
|
|
21
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
|
|
22
|
Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y,
Xu JS, Huang SM, Wang LN, Huang W, et al: Modified glomerular
filtration rate estimating equation for Chinese patients with
chronic kidney disease. J Am Soc Nephrol. 17:2937–2944. 2006.
|
|
23
|
Russo P: End stage and chronic kidney
disease: associations with renal cancer. Front Oncol. 2:282012.
|
|
24
|
Go AS, Chertow GM, Fan D, McCulloch CE and
Hsu CY: Chronic kidney disease and the risks of death,
cardiovascular events, and hospitalization. N Engl J Med.
351:1296–1305. 2004.
|
|
25
|
Ritchey ML, Green DM, Thomas PR, Smith GR,
Haase G, Shochat S, Moksness J and Breslow NE: Renal failure in
Wilms’ tumor patients: a report from the National Wilms’ Tumor
Study Group. Med Pediatr Oncol. 26:75–80. 1996.
|
|
26
|
Cassady JR: Clinical radiation
nephropathy. Int J Radiat Oncol Biol Phys. 31:1249–1256. 1995.
|
